Vertex reaches deal with Wales for cystic fibrosis treatment

[November 13, 2019]  (Reuters) - Vertex Pharmaceuticals Inc said on Wednesday cystic fibrosis patients in Wales would get access to the company's life-extending drugs following an agreement with the state-funded health service.

The U.S. drugmaker has already reached similar agreements with the National Health Service in Northern Ireland, England and Scotland.

More than 10,000 people in Britain have cystic fibrosis, a debilitating, life-shortening inherited condition.

The agreement with Wales will allow about 270 eligible patients to be treated with the company's medicines Orkambi, Symkevi and Kalydeco.

(Reporting by Dania Nadeem in Bengaluru; Editing by Sriraj Kalluvila)

[© 2019 Thomson Reuters. All rights reserved.]

Copyright 2019 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.